New SPRAVATO® (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
confirm its effectiveness and tolerability in a real-world patient population, which on average had severe, chronic, treatment-resistant depression (TRD). The study offers distinct new insight into the durability of treatment effect, with symptom stability maintained across 6 months following discontinuation of esketamine NS. BEERSE, BELGIUM, March 28, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data from the ECHO study which support the effectiveness and safety profile of SPRAVATO ® (esketamine NS) and indicate durability of treatment effect across 6 months after treatment discontinuation in a real-world setting for patients with TRD. These data are being presented at this year's European Psychiatric Association (EPA) Congress, taking place March 28-31, in Prague, Czech Republic. Key study findings reinforce robust effectiveness of esketamine NS From across Europe and Israel, 570 patients started the variable treatment period (TP) (mean duration of 9 months
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson (JNJ) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $255.00 price target on the stock.MarketBeat
- The Low-Volatility Promise of ACWV Costs Investors 118% Over a Decade Compared to SPY [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases [Yahoo! Finance]Yahoo! Finance
- AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson Oncology And Immunology Advances Test Valuation Story [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website